Mineralys Therapeutics heads into its May 21 first-quarter earnings report with one of the more unusual positioning setups in small-cap biotech: short sellers are covering aggressively while options traders have swung to their most bullish stance in a year.
The short interest story is the clearest signal. Short interest fell more than 11% over the past week, dropping to 10.8% of the free float — still elevated in absolute terms, but the direction of travel is sharply lower. The covering accelerated after a peak above 9.6 million shares in early May. Despite that elevated level, borrow conditions remain surprisingly loose: availability runs at over 1,390% of current short interest, meaning the lending pool is nowhere near stressed, and the cost to borrow is a negligible 0.5%. That combination — meaningful short interest with easy borrow — suggests the shorts who remain are well-funded and deliberate, rather than squeezed or trapped.
Options positioning has flipped in the opposite direction. Call demand has surged relative to recent norms: the put/call ratio dropped to 0.60 on Monday — its lowest reading in the past year and nearly two standard deviations below its 20-day average of 0.66. The move is abrupt. For the prior three weeks, the ratio tracked consistently in the 0.67–0.71 range; the sudden tilt toward calls into the print suggests traders are positioning for an upside surprise rather than hedging against a miss. That said, the broader peer group has been weak. Close correlates , , and fell 8–17% on the week, while shed a more contained 7.3% — a relative resilience worth noting given the sector pressure.
The analyst community remains firmly constructive, though recent activity has been limited. TD Cowen initiated coverage with a Buy in late April. Bank of America raised its target to $51 in March after maintaining Buy. The consensus mean target of $48.50 implies roughly 77% upside from the current price of $27.38 — a wide gap that reflects continued confidence in lorundrostat's 10mmHg-plus placebo-adjusted blood pressure benefit in resistant hypertension, and anticipation of a near-term NDA submission. Bears counter with real concerns: commercialisation execution risk, pricing uncertainty, the hyperkalemia tolerability question, and a balance sheet that depends on continued capital access. The ORTEX short score of 58.4 — elevated but easing from a recent peak near 60.3 — captures that unresolved tension without resolving it. Insider activity adds a mild note of caution: the Chief Medical Officer sold shares across multiple dates in April and May, and the CEO sold in mid-April, though both at modest size and consistent with routine plan-based activity.
Thursday's print is therefore less a test of the science — the blood pressure data is well-established — and more a test of whether Mineralys can articulate a credible path from clinical success to commercial reality.
See the live data behind this article on ORTEX.
Open MLYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
